WO2007096078A1 - Use of resveratrol and derivatives thereof for promoting the wellness state in mammals - Google Patents
Use of resveratrol and derivatives thereof for promoting the wellness state in mammals Download PDFInfo
- Publication number
- WO2007096078A1 WO2007096078A1 PCT/EP2007/001256 EP2007001256W WO2007096078A1 WO 2007096078 A1 WO2007096078 A1 WO 2007096078A1 EP 2007001256 W EP2007001256 W EP 2007001256W WO 2007096078 A1 WO2007096078 A1 WO 2007096078A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- resveratrol
- protein
- metabolite
- analogue
- derivative
- Prior art date
Links
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 title claims abstract description 70
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 235000021283 resveratrol Nutrition 0.000 title claims abstract description 64
- 229940016667 resveratrol Drugs 0.000 title claims abstract description 64
- 241000124008 Mammalia Species 0.000 title claims abstract description 38
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims abstract description 54
- 239000002207 metabolite Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000002417 nutraceutical Substances 0.000 claims abstract description 12
- 235000021436 nutraceutical agent Nutrition 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 11
- 235000013361 beverage Nutrition 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 6
- 239000002778 food additive Substances 0.000 claims 1
- 235000013373 food additive Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 241000699660 Mus musculus Species 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- 230000013632 homeostatic process Effects 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000008859 change Effects 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 230000035790 physiological processes and functions Effects 0.000 description 9
- 230000003716 rejuvenation Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000019522 cellular metabolic process Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 7
- 238000001243 protein synthesis Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000012423 maintenance Methods 0.000 description 6
- 230000003340 mental effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 230000009097 homeostatic mechanism Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000037353 metabolic pathway Effects 0.000 description 5
- 230000012846 protein folding Effects 0.000 description 5
- 230000009145 protein modification Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- -1 aromatic carboxylic acids Chemical class 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102100031901 A-kinase anchor protein 2 Human genes 0.000 description 3
- 101710109888 A-kinase anchor protein 2 Proteins 0.000 description 3
- 101710199745 F-box only protein 9 Proteins 0.000 description 3
- 102100029186 F-box only protein 9 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 108010042283 HSP40 Heat-Shock Proteins Proteins 0.000 description 3
- 102000004447 HSP40 Heat-Shock Proteins Human genes 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000037054 SLC-Transporter Human genes 0.000 description 3
- 108091006207 SLC-Transporter Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 235000021579 juice concentrates Nutrition 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000004844 protein turnover Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KTLRRKBJXAJHJD-UHFFFAOYSA-N 4-[2-(3,5-dihydroxyphenyl)ethyl]benzene-1,2-diol Chemical compound OC1=CC(O)=CC(CCC=2C=C(O)C(O)=CC=2)=C1 KTLRRKBJXAJHJD-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 102100031565 Cytidine and dCMP deaminase domain-containing protein 1 Human genes 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 108010089760 Electron Transport Complex I Proteins 0.000 description 2
- 102000008013 Electron Transport Complex I Human genes 0.000 description 2
- 102100031334 Elongation factor 2 Human genes 0.000 description 2
- 241001226424 Erato <angiosperm> Species 0.000 description 2
- 101710139370 Eukaryotic translation elongation factor 2 Proteins 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 102000017278 Glutaredoxin Human genes 0.000 description 2
- 108050005205 Glutaredoxin Proteins 0.000 description 2
- 101000777693 Homo sapiens Cytidine and dCMP deaminase domain-containing protein 1 Proteins 0.000 description 2
- 101000685655 Homo sapiens Long-chain fatty acid transport protein 1 Proteins 0.000 description 2
- 101001079084 Homo sapiens Ras-related protein Rab-18 Proteins 0.000 description 2
- 101000707534 Homo sapiens Serine incorporator 1 Proteins 0.000 description 2
- 101000661819 Homo sapiens Serine/threonine-protein kinase 17B Proteins 0.000 description 2
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 description 2
- 101000777220 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 3 Proteins 0.000 description 2
- 101000802734 Homo sapiens eIF5-mimic protein 2 Proteins 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 108010062228 Karyopherins Proteins 0.000 description 2
- 102000011781 Karyopherins Human genes 0.000 description 2
- 108010059881 Lactase Proteins 0.000 description 2
- 102100023111 Long-chain fatty acid transport protein 1 Human genes 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 102000015097 RNA Splicing Factors Human genes 0.000 description 2
- 108010039259 RNA Splicing Factors Proteins 0.000 description 2
- 102100028149 Ras-related protein Rab-18 Human genes 0.000 description 2
- 102100037875 RelA-associated inhibitor Human genes 0.000 description 2
- 101710201119 RelA-associated inhibitor Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102100031707 Serine incorporator 1 Human genes 0.000 description 2
- 102100037959 Serine/threonine-protein kinase 17B Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 description 2
- 102100021461 Sphingomyelin phosphodiesterase 3 Human genes 0.000 description 2
- 101710201918 Sphingomyelin phosphodiesterase 3 Proteins 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100031287 Ubiquitin carboxyl-terminal hydrolase 3 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010001 cellular homeostasis Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- HITJFUSPLYBJPE-UHFFFAOYSA-N dihydroresveratrol Chemical compound C1=CC(O)=CC=C1CCC1=CC(O)=CC(O)=C1 HITJFUSPLYBJPE-UHFFFAOYSA-N 0.000 description 2
- 102100035859 eIF5-mimic protein 2 Human genes 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 238000003500 gene array Methods 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 229940116108 lactase Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 235000020374 simple syrup Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000008646 thermal stress Effects 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 235000021558 10% juice Nutrition 0.000 description 1
- YHPKGSLWSUCJQK-UHFFFAOYSA-N 2-[[2-[[2-[[2-[[2-[[2-[[5-amino-2-[[2-[(2,4-diamino-4-oxobutanoyl)amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-carboxypropanoyl]amino]-5-(diaminomethylideneamino) Chemical compound NC(N)=NCCCC(C(=O)NC(C(C)C)C(O)=O)NC(=O)C(CC(O)=O)NC(=O)C(CCSC)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(N)CC(N)=O YHPKGSLWSUCJQK-UHFFFAOYSA-N 0.000 description 1
- 102100035352 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial Human genes 0.000 description 1
- 101710177818 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial Proteins 0.000 description 1
- 102100029442 28S ribosomal protein S22, mitochondrial Human genes 0.000 description 1
- 102100039772 39S ribosomal protein L27, mitochondrial Human genes 0.000 description 1
- 102100034140 39S ribosomal protein L43, mitochondrial Human genes 0.000 description 1
- 102100028109 39S ribosomal protein L50, mitochondrial Human genes 0.000 description 1
- 102100039222 5'-3' exoribonuclease 2 Human genes 0.000 description 1
- 101710094877 5'-3' exoribonuclease 2 Proteins 0.000 description 1
- KPFFMALTIRFAHW-UHFFFAOYSA-N 5-[2-(4-hydroxy-3-methoxyphenyl)ethyl]benzene-1,3-diol Chemical compound C1=C(O)C(OC)=CC(CCC=2C=C(O)C=C(O)C=2)=C1 KPFFMALTIRFAHW-UHFFFAOYSA-N 0.000 description 1
- 102100025601 60S ribosomal protein L27 Human genes 0.000 description 1
- RFWGABANNQMHMZ-UHFFFAOYSA-N 8-acetoxy-7-acetyl-6,7,7a,8-tetrahydro-5H-benzo[g][1,3]dioxolo[4',5':4,5]benzo[1,2,3-de]quinoline Natural products CC=C1C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O RFWGABANNQMHMZ-UHFFFAOYSA-N 0.000 description 1
- 108010016281 ADP-Ribosylation Factor 1 Proteins 0.000 description 1
- 102100034341 ADP-ribosylation factor 1 Human genes 0.000 description 1
- 102100040193 ADP-ribosylation factor-binding protein GGA3 Human genes 0.000 description 1
- 102100024120 AP-4 complex accessory subunit RUSC1 Human genes 0.000 description 1
- 102100026135 ATP-dependent RNA helicase DDX24 Human genes 0.000 description 1
- 102100028247 Abl interactor 1 Human genes 0.000 description 1
- 108050004693 Abl interactor 1 Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 101000983256 Acanthamoeba polyphaga mimivirus Putative prolyl 4-hydroxylase Proteins 0.000 description 1
- 102100020963 Actin-binding LIM protein 1 Human genes 0.000 description 1
- 101710123570 Actin-binding LIM protein 1 Proteins 0.000 description 1
- 102000004373 Actin-related protein 2 Human genes 0.000 description 1
- 108090000963 Actin-related protein 2 Proteins 0.000 description 1
- 102000003741 Actin-related protein 3 Human genes 0.000 description 1
- 108090000104 Actin-related protein 3 Proteins 0.000 description 1
- 102100025854 Acyl-coenzyme A thioesterase 1 Human genes 0.000 description 1
- 101710175445 Acyl-coenzyme A thioesterase 1 Proteins 0.000 description 1
- 102100025851 Acyl-coenzyme A thioesterase 2, mitochondrial Human genes 0.000 description 1
- 102000010646 Adaptor Protein Complex 3 Human genes 0.000 description 1
- 108010077835 Adaptor Protein Complex 3 Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 102100039660 Adenylate cyclase type 4 Human genes 0.000 description 1
- 102100032158 Adenylate cyclase type 6 Human genes 0.000 description 1
- 108010031132 Alcohol Oxidoreductases Proteins 0.000 description 1
- 102000005751 Alcohol Oxidoreductases Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100040357 Angiomotin-like protein 1 Human genes 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108050005845 Annexin A11 Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100295091 Arabidopsis thaliana NUDT14 gene Proteins 0.000 description 1
- 102100031464 Armadillo repeat protein deleted in velo-cardio-facial syndrome Human genes 0.000 description 1
- 108050004726 Armadillo repeat protein deleted in velo-cardio-facial syndrome Proteins 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015827 Asporin Human genes 0.000 description 1
- 108050004044 Asporin Proteins 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 102100027954 BAG family molecular chaperone regulator 3 Human genes 0.000 description 1
- 101710089791 BAG family molecular chaperone regulator 3 Proteins 0.000 description 1
- 102100023973 Bax inhibitor 1 Human genes 0.000 description 1
- 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 102100021251 Beclin-1 Human genes 0.000 description 1
- 108090000524 Beclin-1 Proteins 0.000 description 1
- 102100034321 Beta-centractin Human genes 0.000 description 1
- 101710098427 Beta-centractin Proteins 0.000 description 1
- 102100036200 Bisphosphoglycerate mutase Human genes 0.000 description 1
- 102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 description 1
- 101150047144 CDC28 gene Proteins 0.000 description 1
- 102100024301 COMM domain-containing protein 3 Human genes 0.000 description 1
- 101100477827 Caenorhabditis elegans smu-1 gene Proteins 0.000 description 1
- 101100316119 Caenorhabditis elegans unc-52 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100025926 Calmodulin-3 Human genes 0.000 description 1
- 101710164738 Calmodulin-3 Proteins 0.000 description 1
- 102100025168 Calpain-15 Human genes 0.000 description 1
- 102100038613 Calreticulin-3 Human genes 0.000 description 1
- 101710160266 Calreticulin-3 Proteins 0.000 description 1
- 102100028801 Calsyntenin-1 Human genes 0.000 description 1
- 101710193358 Calsyntenin-1 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 102000011937 Cathepsin Z Human genes 0.000 description 1
- 108010061117 Cathepsin Z Proteins 0.000 description 1
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102100031082 Choline/ethanolamine kinase Human genes 0.000 description 1
- 102100038214 Chromodomain-helicase-DNA-binding protein 4 Human genes 0.000 description 1
- 101710170308 Chromodomain-helicase-DNA-binding protein 4 Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102100024252 Coatomer subunit zeta-1 Human genes 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102100035590 Cohesin subunit SA-1 Human genes 0.000 description 1
- 101710173923 Cohesin subunit SA-1 Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100021899 Cyclin-L2 Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102100031621 Cysteine and glycine-rich protein 2 Human genes 0.000 description 1
- 101710185482 Cysteine and glycine-rich protein 2 Proteins 0.000 description 1
- 102100027419 Cytochrome P450 4B1 Human genes 0.000 description 1
- 102000005362 Cytoplasmic Dyneins Human genes 0.000 description 1
- 108010070977 Cytoplasmic Dyneins Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102100029583 DDB1- and CUL4-associated factor 5 Human genes 0.000 description 1
- 102100025269 DENN domain-containing protein 2B Human genes 0.000 description 1
- 101710141585 DENN domain-containing protein 2B Proteins 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 102100036674 DNA damage-binding protein 1 Human genes 0.000 description 1
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 1
- 101710119265 DNA topoisomerase 1 Proteins 0.000 description 1
- 102100036500 Dehydrogenase/reductase SDR family member 7 Human genes 0.000 description 1
- HKVGJQVJNQRJPO-UHFFFAOYSA-N Demethyloleuropein Natural products O1C=C(C(O)=O)C(CC(=O)OCCC=2C=C(O)C(O)=CC=2)C(=CC)C1OC1OC(CO)C(O)C(O)C1O HKVGJQVJNQRJPO-UHFFFAOYSA-N 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102100037417 Dexamethasone-induced protein Human genes 0.000 description 1
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
- 102100028572 Disabled homolog 2 Human genes 0.000 description 1
- 101710197163 Disabled homolog 2 Proteins 0.000 description 1
- 102100029707 DnaJ homolog subfamily B member 4 Human genes 0.000 description 1
- 102100029701 DnaJ homolog subfamily B member 5 Human genes 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 108010038530 Dual Specificity Phosphatase 6 Proteins 0.000 description 1
- 102000010779 Dual Specificity Phosphatase 6 Human genes 0.000 description 1
- 102100037570 Dual specificity protein phosphatase 16 Human genes 0.000 description 1
- 102100023965 Dynein light chain Tctex-type 3 Human genes 0.000 description 1
- 101710150624 Dynein light chain Tctex-type 3 Proteins 0.000 description 1
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 description 1
- 108091012458 E3 ubiquitin-protein ligase RING2 Proteins 0.000 description 1
- 102100028090 E3 ubiquitin-protein ligase RNF114 Human genes 0.000 description 1
- 101710162464 E3 ubiquitin-protein ligase RNF114 Proteins 0.000 description 1
- 102100034165 E3 ubiquitin-protein ligase RNF13 Human genes 0.000 description 1
- 101710109051 E3 ubiquitin-protein ligase RNF13 Proteins 0.000 description 1
- 101000742439 Enterobacteria phage T4 Head formation protein Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000002241 Eukaryotic Initiation Factors Human genes 0.000 description 1
- 108010014863 Eukaryotic Initiation Factors Proteins 0.000 description 1
- 102100027304 Eukaryotic translation initiation factor 4E Human genes 0.000 description 1
- 101710091918 Eukaryotic translation initiation factor 4E Proteins 0.000 description 1
- 102100032833 Exportin-4 Human genes 0.000 description 1
- 101710147879 Exportin-4 Proteins 0.000 description 1
- 102100036123 Far upstream element-binding protein 2 Human genes 0.000 description 1
- 101710133942 Far upstream element-binding protein 2 Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100033063 G protein-activated inward rectifier potassium channel 1 Human genes 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 description 1
- 101710117710 GTPase activating protein 1 Proteins 0.000 description 1
- 102000007563 Galectins Human genes 0.000 description 1
- 108010046569 Galectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710092774 Glyoxalase 1 Proteins 0.000 description 1
- 108010052778 Golgi Matrix Proteins Proteins 0.000 description 1
- 102000018884 Golgi Matrix Proteins Human genes 0.000 description 1
- 102100032560 Golgin subfamily A member 4 Human genes 0.000 description 1
- 102100041033 Golgin subfamily B member 1 Human genes 0.000 description 1
- 102100040017 Growth hormone-inducible transmembrane protein Human genes 0.000 description 1
- 101710185632 Growth hormone-inducible transmembrane protein Proteins 0.000 description 1
- 102000007548 Guanine Nucleotide-Releasing Factor 2 Human genes 0.000 description 1
- 108010085877 Guanine Nucleotide-Releasing Factor 2 Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 102100031497 Heparan sulfate N-sulfotransferase 1 Human genes 0.000 description 1
- 102100039236 Histone H3.3 Human genes 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 108700038332 Histone deacetylase 11 Proteins 0.000 description 1
- 102100022103 Histone-lysine N-methyltransferase 2A Human genes 0.000 description 1
- 108050002855 Histone-lysine N-methyltransferase 2A Proteins 0.000 description 1
- 102100024594 Histone-lysine N-methyltransferase PRDM16 Human genes 0.000 description 1
- 102100035009 Holocytochrome c-type synthase Human genes 0.000 description 1
- 101000699890 Homo sapiens 28S ribosomal protein S22, mitochondrial Proteins 0.000 description 1
- 101000667433 Homo sapiens 39S ribosomal protein L27, mitochondrial Proteins 0.000 description 1
- 101000711507 Homo sapiens 39S ribosomal protein L43, mitochondrial Proteins 0.000 description 1
- 101001079824 Homo sapiens 39S ribosomal protein L50, mitochondrial Proteins 0.000 description 1
- 101000719728 Homo sapiens 60S ribosomal protein L27 Proteins 0.000 description 1
- 101001037079 Homo sapiens ADP-ribosylation factor-binding protein GGA3 Proteins 0.000 description 1
- 101000690135 Homo sapiens AP-4 complex accessory subunit RUSC1 Proteins 0.000 description 1
- 101000912684 Homo sapiens ATP-dependent RNA helicase DDX24 Proteins 0.000 description 1
- 101000720371 Homo sapiens Acyl-coenzyme A thioesterase 2, mitochondrial Proteins 0.000 description 1
- 101000959333 Homo sapiens Adenylate cyclase type 4 Proteins 0.000 description 1
- 101000891169 Homo sapiens Angiomotin-like protein 1 Proteins 0.000 description 1
- 101000903937 Homo sapiens Bax inhibitor 1 Proteins 0.000 description 1
- 101000798320 Homo sapiens Bcl-2 homologous antagonist/killer Proteins 0.000 description 1
- 101000594702 Homo sapiens Bisphosphoglycerate mutase Proteins 0.000 description 1
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 description 1
- 101000909562 Homo sapiens COMM domain-containing protein 3 Proteins 0.000 description 1
- 101000934071 Homo sapiens Calpain-15 Proteins 0.000 description 1
- 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 1
- 101000909614 Homo sapiens Coatomer subunit zeta-1 Proteins 0.000 description 1
- 101000897452 Homo sapiens Cyclin-L2 Proteins 0.000 description 1
- 101000725141 Homo sapiens Cytochrome P450 4B1 Proteins 0.000 description 1
- 101000917422 Homo sapiens DDB1- and CUL4-associated factor 5 Proteins 0.000 description 1
- 101000928758 Homo sapiens Dehydrogenase/reductase SDR family member 7 Proteins 0.000 description 1
- 101000806442 Homo sapiens Dexamethasone-induced protein Proteins 0.000 description 1
- 101000866008 Homo sapiens DnaJ homolog subfamily B member 4 Proteins 0.000 description 1
- 101000866011 Homo sapiens DnaJ homolog subfamily B member 5 Proteins 0.000 description 1
- 101000881117 Homo sapiens Dual specificity protein phosphatase 16 Proteins 0.000 description 1
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 description 1
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 101001014636 Homo sapiens Golgin subfamily A member 4 Proteins 0.000 description 1
- 101000588589 Homo sapiens Heparan sulfate N-sulfotransferase 1 Proteins 0.000 description 1
- 101001035966 Homo sapiens Histone H3.3 Proteins 0.000 description 1
- 101000686942 Homo sapiens Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 description 1
- 101000946589 Homo sapiens Holocytochrome c-type synthase Proteins 0.000 description 1
- 101001035137 Homo sapiens Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein Proteins 0.000 description 1
- 101000599629 Homo sapiens Insulin-induced gene 2 protein Proteins 0.000 description 1
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 1
- 101000971697 Homo sapiens Kinesin-like protein KIF1B Proteins 0.000 description 1
- 101000604876 Homo sapiens Kremen protein 1 Proteins 0.000 description 1
- 101001018300 Homo sapiens Microtubule-associated serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101000951306 Homo sapiens Mitoferrin-2 Proteins 0.000 description 1
- 101001128456 Homo sapiens Myosin regulatory light polypeptide 9 Proteins 0.000 description 1
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 description 1
- 101000979323 Homo sapiens NHP2-like protein 1 Proteins 0.000 description 1
- 101001123834 Homo sapiens Neprilysin Proteins 0.000 description 1
- 101000577541 Homo sapiens Neuronal regeneration-related protein Proteins 0.000 description 1
- 101000978924 Homo sapiens Nuclear receptor subfamily 1 group D member 2 Proteins 0.000 description 1
- 101000613798 Homo sapiens OTU domain-containing protein 7B Proteins 0.000 description 1
- 101001134134 Homo sapiens Oxidation resistance protein 1 Proteins 0.000 description 1
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 1
- 101001134861 Homo sapiens Pericentriolar material 1 protein Proteins 0.000 description 1
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 description 1
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 1
- 101000873615 Homo sapiens Protein bicaudal D homolog 2 Proteins 0.000 description 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101001132256 Homo sapiens Ras-related protein Rab-28 Proteins 0.000 description 1
- 101001132279 Homo sapiens Ras-related protein Rab-2A Proteins 0.000 description 1
- 101001060852 Homo sapiens Ras-related protein Rab-34 Proteins 0.000 description 1
- 101001128094 Homo sapiens Ras-related protein Rab-34, isoform NARR Proteins 0.000 description 1
- 101000709305 Homo sapiens Replication protein A 14 kDa subunit Proteins 0.000 description 1
- 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 description 1
- 101000707471 Homo sapiens Serine incorporator 3 Proteins 0.000 description 1
- 101000601460 Homo sapiens Serine/threonine-protein kinase Nek4 Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101000783373 Homo sapiens Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Proteins 0.000 description 1
- 101000806155 Homo sapiens Short-chain dehydrogenase/reductase 3 Proteins 0.000 description 1
- 101000640823 Homo sapiens Sodium-coupled neutral amino acid transporter 3 Proteins 0.000 description 1
- 101000974834 Homo sapiens Sodium/potassium-transporting ATPase subunit beta-3 Proteins 0.000 description 1
- 101000629631 Homo sapiens Sorbin and SH3 domain-containing protein 1 Proteins 0.000 description 1
- 101000648196 Homo sapiens Striatin Proteins 0.000 description 1
- 101000740523 Homo sapiens Syntenin-1 Proteins 0.000 description 1
- 101000596277 Homo sapiens TSC22 domain family protein 3 Proteins 0.000 description 1
- 101001027052 Homo sapiens Thymidylate kinase Proteins 0.000 description 1
- 101000836148 Homo sapiens Transforming acidic coiled-coil-containing protein 2 Proteins 0.000 description 1
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 description 1
- 101000658574 Homo sapiens Transmembrane 4 L6 family member 1 Proteins 0.000 description 1
- 101000645421 Homo sapiens Transmembrane protein 165 Proteins 0.000 description 1
- 101000800287 Homo sapiens Tubulointerstitial nephritis antigen-like Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 101001065732 Homo sapiens U6 snRNA-associated Sm-like protein LSm6 Proteins 0.000 description 1
- 101000777156 Homo sapiens UBX domain-containing protein 4 Proteins 0.000 description 1
- 101000777142 Homo sapiens UBX domain-containing protein 6 Proteins 0.000 description 1
- 101000809243 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 10 Proteins 0.000 description 1
- 101000662296 Homo sapiens Ubiquitin-like protein 4A Proteins 0.000 description 1
- 101000806266 Homo sapiens Very-long-chain 3-oxoacyl-CoA reductase Proteins 0.000 description 1
- 101000654430 Homo sapiens Vesicle-trafficking protein SEC22a Proteins 0.000 description 1
- 101000814304 Homo sapiens WW domain-binding protein 2 Proteins 0.000 description 1
- 101000804890 Homo sapiens Xin actin-binding repeat-containing protein 1 Proteins 0.000 description 1
- 101000785632 Homo sapiens Zinc finger FYVE domain-containing protein 21 Proteins 0.000 description 1
- 102100039923 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 protein Human genes 0.000 description 1
- 102000003856 Hypoxia-inducible factor-proline dioxygenases Human genes 0.000 description 1
- 108090000223 Hypoxia-inducible factor-proline dioxygenases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100037970 Insulin-induced gene 2 protein Human genes 0.000 description 1
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 1
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 1
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 102100021524 Kinesin-like protein KIF1B Human genes 0.000 description 1
- 102100038173 Kremen protein 1 Human genes 0.000 description 1
- 102100020684 Krueppel-like factor 9 Human genes 0.000 description 1
- 101710116942 Krueppel-like factor 9 Proteins 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 102100029825 Leptin receptor gene-related protein Human genes 0.000 description 1
- 101710098736 Leptin receptor gene-related protein Proteins 0.000 description 1
- 102100032114 Lumican Human genes 0.000 description 1
- 108010076371 Lumican Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102100026395 Lysine-specific demethylase PHF2 Human genes 0.000 description 1
- 101710128369 Lysine-specific demethylase phf2 Proteins 0.000 description 1
- 108010075647 MAP Kinase Kinase Kinase 4 Proteins 0.000 description 1
- 102000042257 MAPRE family Human genes 0.000 description 1
- 108091077621 MAPRE family Proteins 0.000 description 1
- 102100038884 Major vault protein Human genes 0.000 description 1
- 101710094960 Major vault protein Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 102100022465 Methanethiol oxidase Human genes 0.000 description 1
- 101710134383 Methanethiol oxidase Proteins 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100027383 Methyl-CpG-binding domain protein 1 Human genes 0.000 description 1
- 101710111887 Methyl-CpG-binding domain protein 1 Proteins 0.000 description 1
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100036203 Microfibrillar-associated protein 5 Human genes 0.000 description 1
- 101710147471 Microfibrillar-associated protein 5 Proteins 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 102100021794 Microtubule-associated protein 4 Human genes 0.000 description 1
- 101710093519 Microtubule-associated protein 4 Proteins 0.000 description 1
- 102100033253 Microtubule-associated serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100037989 Mitoferrin-2 Human genes 0.000 description 1
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 102100021286 Multiple PDZ domain protein Human genes 0.000 description 1
- 101710093002 Multiple PDZ domain protein Proteins 0.000 description 1
- 101001012964 Mus musculus EH domain-binding protein 1-like protein 1 Proteins 0.000 description 1
- 101000812646 Mus musculus Endoplasmin Proteins 0.000 description 1
- 101000979318 Mus musculus NHP2-like protein 1 Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 102000046234 Myeloid Cell Leukemia Sequence 1 Human genes 0.000 description 1
- 108700006140 Myeloid Cell Leukemia Sequence 1 Proteins 0.000 description 1
- 102100032965 Myomesin-2 Human genes 0.000 description 1
- 101710106572 Myomesin-2 Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 102100031787 Myosin regulatory light polypeptide 9 Human genes 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102100023052 NEDD4 family-interacting protein 2 Human genes 0.000 description 1
- 101710125378 NEDD4 family-interacting protein 2 Proteins 0.000 description 1
- 102100023058 NHP2-like protein 1 Human genes 0.000 description 1
- 102100028782 Neprilysin Human genes 0.000 description 1
- 102100028745 Neuronal regeneration-related protein Human genes 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 102100021133 Nuclear protein 1 Human genes 0.000 description 1
- 101710170054 Nuclear protein 1 Proteins 0.000 description 1
- 102100023171 Nuclear receptor subfamily 1 group D member 2 Human genes 0.000 description 1
- 102100040562 OTU domain-containing protein 7B Human genes 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- RFWGABANNQMHMZ-HYYSZPHDSA-N Oleuropein Chemical compound O([C@@H]1OC=C([C@H](C1=CC)CC(=O)OCCC=1C=C(O)C(O)=CC=1)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RFWGABANNQMHMZ-HYYSZPHDSA-N 0.000 description 1
- 102100031822 Optineurin Human genes 0.000 description 1
- 101710131459 Optineurin Proteins 0.000 description 1
- 102100034219 Oxidation resistance protein 1 Human genes 0.000 description 1
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 102100036978 Peptidyl-prolyl cis-trans isomerase FKBP8 Human genes 0.000 description 1
- 101710147137 Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 description 1
- 102100033422 Pericentriolar material 1 protein Human genes 0.000 description 1
- 241000283089 Perissodactyla Species 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 1
- 102100035367 Phosphomannomutase 1 Human genes 0.000 description 1
- 101710133556 Phosphomannomutase 1 Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 description 1
- 102100036031 Podocalyxin Human genes 0.000 description 1
- 102100034961 Poly(rC)-binding protein 2 Human genes 0.000 description 1
- 101710089647 Poly(rC)-binding protein 2 Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100029245 Probable RNA-binding protein 18 Human genes 0.000 description 1
- 101710150107 Probable RNA-binding protein 18 Proteins 0.000 description 1
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100035900 Protein bicaudal D homolog 2 Human genes 0.000 description 1
- 102100040923 Protein flightless-1 homolog Human genes 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 102000015176 Proton-Translocating ATPases Human genes 0.000 description 1
- 108010039518 Proton-Translocating ATPases Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 102100034489 Ras-related protein Rab-28 Human genes 0.000 description 1
- 102100034485 Ras-related protein Rab-2A Human genes 0.000 description 1
- 102100027916 Ras-related protein Rab-34 Human genes 0.000 description 1
- 101000804115 Rattus norvegicus DnaJ homolog subfamily B member 6 Proteins 0.000 description 1
- 102100035772 Regulator of G-protein signaling 12 Human genes 0.000 description 1
- 101710148337 Regulator of G-protein signaling 12 Proteins 0.000 description 1
- 102100034372 Replication protein A 14 kDa subunit Human genes 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- PHMHDRYYFAYWEG-NSCUHMNNSA-N Rhapontigenin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PHMHDRYYFAYWEG-NSCUHMNNSA-N 0.000 description 1
- PHMHDRYYFAYWEG-UHFFFAOYSA-N Rhapontigenin Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(O)=C1 PHMHDRYYFAYWEG-UHFFFAOYSA-N 0.000 description 1
- 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 description 1
- 102100023542 Ribosome-binding protein 1 Human genes 0.000 description 1
- 101710132192 Ribosome-binding protein 1 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- 108010011005 STAT6 Transcription Factor Proteins 0.000 description 1
- 101000592082 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L28 Proteins 0.000 description 1
- 101100189627 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PTC5 gene Proteins 0.000 description 1
- 101100082911 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ppp1 gene Proteins 0.000 description 1
- 101710132826 Selenium-binding protein 1 Proteins 0.000 description 1
- 102000009203 Sema domains Human genes 0.000 description 1
- 108050000099 Sema domains Proteins 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- 108700026518 Sequestosome-1 Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100031727 Serine incorporator 3 Human genes 0.000 description 1
- 102100037705 Serine/threonine-protein kinase Nek4 Human genes 0.000 description 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 1
- 101710168567 Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
- 102100036140 Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform Human genes 0.000 description 1
- 102100027288 Sestrin-1 Human genes 0.000 description 1
- 101710186864 Sestrin-1 Proteins 0.000 description 1
- 102100037857 Short-chain dehydrogenase/reductase 3 Human genes 0.000 description 1
- 102100023980 Signal transducer and activator of transcription 6 Human genes 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102100033769 Sodium-coupled neutral amino acid transporter 3 Human genes 0.000 description 1
- 102100022792 Sodium/potassium-transporting ATPase subunit beta-3 Human genes 0.000 description 1
- 102100026834 Sorbin and SH3 domain-containing protein 1 Human genes 0.000 description 1
- 102100038624 Sorting nexin-5 Human genes 0.000 description 1
- 108050006125 Sorting nexin-5 Proteins 0.000 description 1
- 102100036422 Speckle-type POZ protein Human genes 0.000 description 1
- 101710181896 Speckle-type POZ protein Proteins 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 102100027005 Spindlin-1 Human genes 0.000 description 1
- 102100030510 Stanniocalcin-2 Human genes 0.000 description 1
- 101710142154 Stanniocalcin-2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100028898 Striatin Human genes 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
- 101710139715 Superoxide dismutase [Cu-Zn] Proteins 0.000 description 1
- 102100035581 Synaptojanin-2-binding protein Human genes 0.000 description 1
- 101710155018 Synaptojanin-2-binding protein Proteins 0.000 description 1
- 102100035604 Synaptopodin Human genes 0.000 description 1
- 101710119889 Synaptopodin Proteins 0.000 description 1
- 102100030545 Synaptosomal-associated protein 23 Human genes 0.000 description 1
- 101710189545 Synaptosomal-associated protein 23 Proteins 0.000 description 1
- 102100028808 Syntaxin-8 Human genes 0.000 description 1
- 102100037219 Syntenin-1 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102100035260 TSC22 domain family protein 3 Human genes 0.000 description 1
- 102100040952 Tetraspanin-7 Human genes 0.000 description 1
- 101710151639 Tetraspanin-7 Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 108010046722 Thrombospondin 1 Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102100037357 Thymidylate kinase Human genes 0.000 description 1
- 102100028702 Thyroid hormone receptor alpha Human genes 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102100031142 Transcriptional repressor protein YY1 Human genes 0.000 description 1
- 102100027044 Transforming acidic coiled-coil-containing protein 2 Human genes 0.000 description 1
- 102100031232 Transient receptor potential cation channel subfamily M member 7 Human genes 0.000 description 1
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 description 1
- 102100025755 Transmembrane protein 165 Human genes 0.000 description 1
- 102100028746 Transportin-3 Human genes 0.000 description 1
- 101710120730 Transportin-3 Proteins 0.000 description 1
- 102100029709 Tripartite motif-containing protein 54 Human genes 0.000 description 1
- 101710154817 Tripartite motif-containing protein 54 Proteins 0.000 description 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
- 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 1
- 101710186379 Tropomyosin-1 Proteins 0.000 description 1
- 102100033469 Tubulointerstitial nephritis antigen-like Human genes 0.000 description 1
- 101710102803 Tumor suppressor ARF Proteins 0.000 description 1
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 102100032068 U6 snRNA-associated Sm-like protein LSm6 Human genes 0.000 description 1
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 description 1
- 102100031309 UBX domain-containing protein 6 Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100038426 Ubiquitin carboxyl-terminal hydrolase 10 Human genes 0.000 description 1
- 102100037842 Ubiquitin-like protein 4A Human genes 0.000 description 1
- 108020000963 Uroporphyrinogen-III synthase Proteins 0.000 description 1
- 102100039543 Uveal autoantigen with coiled-coil domains and ankyrin repeats Human genes 0.000 description 1
- 101710090735 Uveal autoantigen with coiled-coil domains and ankyrin repeats Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100037438 Very-long-chain 3-oxoacyl-CoA reductase Human genes 0.000 description 1
- 108010017749 Vesicle-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102000004604 Vesicle-Associated Membrane Protein 3 Human genes 0.000 description 1
- 102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 1
- 108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 1
- 102100031495 Vesicle-trafficking protein SEC22a Human genes 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102100039412 WW domain-binding protein 2 Human genes 0.000 description 1
- 102100036960 Xin actin-binding repeat-containing protein 1 Human genes 0.000 description 1
- 108010042669 YY1 Transcription Factor Proteins 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 102100026462 Zinc finger FYVE domain-containing protein 21 Human genes 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100040824 Zinc finger protein 397 Human genes 0.000 description 1
- 101710146661 Zinc finger protein 397 Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 108010023957 adenylyl cyclase 6 Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004635 cellular health Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 101150077768 ddb1 gene Proteins 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- SLPJGDQJLTYWCI-UHFFFAOYSA-N dimethyl-(4,5,6,7-tetrabromo-1h-benzoimidazol-2-yl)-amine Chemical compound BrC1=C(Br)C(Br)=C2NC(N(C)C)=NC2=C1Br SLPJGDQJLTYWCI-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 102000007336 epsin Human genes 0.000 description 1
- 108010032643 epsin Proteins 0.000 description 1
- 101150092386 erh gene Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000003563 glycoside group Chemical group 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000007166 healthy aging Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 235000014058 juice drink Nutrition 0.000 description 1
- 102000027041 kinase binding proteins Human genes 0.000 description 1
- 108091008508 kinase binding proteins Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 108010053687 macrogolgin Proteins 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000009340 myotonic dystrophy type 1 Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 235000011576 oleuropein Nutrition 0.000 description 1
- RFWGABANNQMHMZ-CARRXEGNSA-N oleuropein Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)C(=CC)[C@H]1CC(=O)OCCc3ccc(O)c(O)c3 RFWGABANNQMHMZ-CARRXEGNSA-N 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 208000027014 optic atrophy 1 Diseases 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- 230000000858 peroxisomal effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000025220 protein targeting to vacuole Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 229940026534 resveratrol 50 mg Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020398 sperm-specific antigen 1 Diseases 0.000 description 1
- 108010068245 spindlin Proteins 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 108091008763 thyroid hormone receptors α Proteins 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- JNOLLWPLUCJHQT-UHFFFAOYSA-N tristin Natural products COc1cccc(CCc2cc(O)cc(O)c2)c1 JNOLLWPLUCJHQT-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 102000003643 uroporphyrinogen-III synthase Human genes 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
Definitions
- the present invention refers to a method for promoting the wellness state of an organism by inducing physiological changes that will give the organism a younger molecular phenotype.
- organ is to be understood to refer to mammals which comprises human beings and animals. Mammals in the context of the present invention include humans, other primates, carnivores, artiodactyla, rodents, perissodactyla, lagomorpha etc. Preferred “mammals” are humans and pets such as cats, dogs and horses.
- Wellness denotes that an organism is able to function optimally under the conditions of its environement. It includes optimal physical and mental functions.
- wellness is defined as a state of general good body function in which all functions of an organism are in optimal working conditions, being free of activity limitations and chronic disorders.
- mobility, physical performance and tolerance to thermal stress are maintained.
- the organism is free from physical disorders, is not damaged and free from pain. It is able to cope with everyday activities and has the flexibility to deal with life's inevitable challenges, thus being physically fit for a high quality of life.
- it is in a state of optimal performance of mental function, resulting in learning and productive activities, it has social connectivity to other individuals and the ability to adapt to changes and to cope with adversity and stress. It is also free from physical alteration and mental problems such as depression, anxiety, cognitive problems, and alterations in thinking, mood or behavior.
- Differences in the wellness of an organism can most strikingly be observed if one compares a young organism with an old organism.
- a difference in the wellness state between a young and an old organism is reflected in differences in their gene expression profiles which can be used as a molecular signature of wellness.
- the state of wellness can be determined, inter alia, by evaluating measurable parameters of body functions, such as, e.g., blood pressure, heart rate, body fat composition, pulmonary function, liver function, brain function and levels of physiologically vital components in body fluids, etc., as disclosed in US patent 5,692,501.
- Promotion of the wellness state denotes an improvement in the general health state of an organism including both physical and mental health and is achieved by inducing physiological changes represented by a change in the gene expression profile of an adult organism typical of higher age to that of the same organism but of lower age.
- the effect of promotion of the wellness state of an organism in accordance with the present invention is a rejuvenating effect resulting in a younger phenotype.
- This rejuvenation effect is different from an anti-aging effect and corresponding treatments which are aimed at delaying the aging process in an organism and ultimately trying to extend its lifespan by preventing loss of physiological functions and age-related diseases.
- the wellness-promoting treatment aims to restore the wellness state of an older organism, thus making it identical or more similar to the wellness state of an equivalent, younger organism.
- Homeostasis is the inherent tendency of an organism towards maintenance of physiological and psychological stability.
- Homeostatic mechanisms in mammals are for example: the regulation of body temperature, the regulation of the amounts of water and minerals in the body, the removal of metabolic waste, the regulation of blood glucose and lipid levels.
- factors such as temperature, salinity, acidity, concentrations of nutrients, such as glucose, lipids, various ions (calcium, sodium, potassium, etc.), oxygen and wastes, such as carbon dioxide and urea must also be maintained within tolerable limits.
- factors such as temperature, salinity, acidity, concentrations of nutrients, such as glucose, lipids, various ions (calcium, sodium, potassium, etc.), oxygen and wastes, such as carbon dioxide and urea must also be maintained within tolerable limits.
- body fluids such as blood plasma, tissue fluid and intracellular fluid to allow the organism to function more effectively.
- cellular components such as proteins, lipid membranes, sugars and nucleic acids
- homeostatic mechanisms are essential for maintenance of the internal environment of an organism within tolerable limits to sustain health and optimal function. This occurs by regulating the metabolism of an organism through numerous metabolic pathways which are series of chemical reactions occurring in cells or whole organisms.
- the metabolism of an organism can be divided in two main processes: (1) the biosynthesis of molecules (anabolism) in which cells use energy to build complex molecules, cellular structure and perform the organism functions and (2) the process for breaking down molecules to produce energy (catabolism).
- the whole organism must also maintain homeostasis between catabolism and anabolism. If an organism loses its normal homeostasis, adverse symptoms developand mechanisms are activated in an attempt to restore balance. If this is not successful, over time disorders will develop. Therefore, chronic imbalances of normal metabolic pathways result in the development of numerous disorders.
- the regulation of metabolism and metabolic pathways to maintain homeostasis are central to the molecular events resulting in health and optimal function or, alternatively, disorders.
- Cellular metabolism is linked to cellular health, and the wellness of an organism is correlated with cellular function in that organism.
- Cellular metabolism is maintained in a state of dynamic equilibrium (homeostasis) by interrelated complex metabolic pathways.
- the cellular responses to stimuli are often a result of coordinated activity of groups of genes which tend to maintain homeostasis.
- the cells respond to internal and external stimuli by changes in gene expression profiles.
- Gene expression profiles can be used as global markers of the status and response of cells, organs and whole organisms and result from changes in the status of proteins and other metabolites.
- a gene expression profile can also be used to identify specific metabolic processes and cellular functions which differ in different individuals. Global gene expression profiling will define the genome wide response occurring during cellular metabolism, and any changes in gene expression will reflect changes in cellular function.
- Gene expression profiles give a global view of the cellular activities and functions reflecting the physiological and wellness states of an organism.
- Microarray technology enables genome-wide gene expression analysis to determine global gene expression in tissues and assess the gene regulation in an organism. Such technology can be used to analyze the expression-pattern and expression-levels of thousands of genes simultaneously. Thus, the transcriptional status of the majority of genes in a particular genome is determined.
- the technique also enables a direct quantitative comparison of the expression level of specific genes in the same tissues from organisms under different physiological conditions, and will provide information on the physiological state of that organism at the molecular level. Changes in gene expression provide the molecular phenotype of a tissue and can be used to discriminate between normal and pathological states, as well as to determine the effect of certain interventions on such physiological states.
- microarray technology is a highly effective tool for understanding the function of dietary nutrients and the global response of an organism to those nutrients.
- a disorder is usually diagnosed by measuring various biomarkers. However, a disorder that results from long-term imbalances in metabolism may not have a measurable biomarker of damage before the disorder is well established. Thus, often when a physician makes a diagnosis the disease is already present. Moreover, it is often not possible to reverse chronic disorders by simply restoring the normal balance of specific aspects of metabolism.
- a change in gene expression is an early event in reaction to a challenge or change in cell processes, and enables the detection and correction of any undesired structural changes at the molecular level and at a very early stage before any damage has occurred, thus maintaining an organism in an optimal physiological or wellness state.
- young organisms have a higher capacity than old organisms to repair and regenerate tissues such as liver, muscle, bone and arterial walls.
- Young adult organisms are more resistant to stress due to their ability to better maintain cellular homeostasis under challenging conditions, compared with old organisms. Young organisms have sensitive homeostatic mechanisms which, in comparison to older organisms, can respond more rapidly to an imbalance in cellular metabolism and canrepair the damage faster thus also decreasing the recovery period after a challenge.
- Young adult organisms are also better able to maintain homeostasis due to their wider dynamic range of conditions within which they can function properly, for example, they have better thermo-regulation and are more resistant to a heat shock (thermal stress) than corresponding older organisms. Young organisms also have a higher capacity to maintain homeostasis by more rapidly removing damaged cells and molecules and having a faster repair and regenerative capacity, thus maintaining the body in a better wellness state.
- Conboy et al. investigated whether this decline is irreversible, or whether it can be modulated by factors in the circulation. They joined together the circulatory systems of young and old mice, as a 'parabiotic' pair and demonstrated that the regenerative capacity of aged muscle and liver were recovered in the presence of serum from younger animals. They also observed that at the same time there was a restoration of a younger molecular signaling profile.
- old cells may regain a younger phenotype when exposed to a young cell environment with a younger molecular cellular signaling profile.
- tissue gene expression profiles were able to be used to predict if humans have kidneys exhibiting an unusual state of wellness or, alternatively, abnormal degeneration for their respective chronological age.
- tissue gene expression profiles were able to be used to predict if humans have kidneys exhibiting an unusual state of wellness or, alternatively, abnormal degeneration for their respective chronological age.
- the same gene varied suggesting that the same molecular differences between old and young cells would occur in all organs, and that there are common mechanisms of aging in all tissues.
- lipids genes involved in the maintenance of normal physiological values of blood cholesterol (lipids), blood triglyceride lipids, blood Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) and the LDL to HDL ratio, blood glucose, liver function, heart rate, protein, vitamin and mineral metabolism, immune system natural killer cell (NK) activity, immune system vitality and proportion of NK cells, immune cells (NK, B and T-cell counts) and immune T-cell helper/suppressor ratio, genes involved in apoptosis, cell adhesion, cell growth and maintenance, cytoskeletal organization, embryonal development, electron transport, endo-exophagocytosis, inflammation/immune response, metabolism of carbohydrates, fatty acids, lipids, nucleic acids, TCA cycle, protein folding, protein synthesis, protein ubiquitination, proteolysis, response to stress, signal transduction, transcription, or transport may be regarded as contributing especially to maintaining and promoting the state of wellness.
- lipids blood trig
- genes involved in the expression of IgFIr, Bcl2 antagonist, cyclooxygenase especially genes involved in protein synthesis, turnover and modification, such as elF4A, 4E, 4gamma1 ,elF3subunit10, eukaryotic translation elongation factor 2, mitochondrial ribosomal protein L43, L27, ARF binding protein3, f- box only protein 9, DnaJ (Hsp40 homolog, Hspibeta etc.) are vital to the maintenance and promotion of wellness.
- the gene expression profile may be used as an indicator of the wellness state of an organism or of a rejuvenating effect.
- the average gene expression profile of a young adult organism can be used as a reference for an optimal physiological state of wellness.
- the state of wellness of an organism could be promoted by creating a younger environment for its cells by changing cellular signaling to a younger profile and as such restoring the capacity to maintain homeostasis and regenerative efficiency and thusalso rejuvenating the organism.
- Genome-wide analysis of gene expression profiles enables the global assessment of the wellness state of a cell, tissue or organism.
- the comparison of the gene expression profile of an organism to that of a healthy younger adult organism can be used as a measure of the global wellness sate of the organism.
- a younger gene expression profile reflects a younger metabolic and signaling profile of a cell or organism, which will be more resistant to internal or external stimuli and, thus, maintains the organism in a better wellness state.
- promotion of the wellness state of a mammal or a rejuvenating effect can be achieved by administering to said mammal an effective amount of resveratrol, a derivative, metabolite or analogue thereof.
- resveratrol a derivative, metabolite or analogue thereof as used herein comprises compounds encompassed by the general formula I
- A denotes a carbon-carbon single or double bond, the latter may be trans or cis, and R1 , R2, R3, R4, R5 and R6, independently from each other denote hydrogen, hydroxy, etherified hydroxy or esterified hydroxy groups.
- Preferred are compounds I wherein A is a double bond (-CH CH-).
- resveratrol a derivative, metabolite or analogue thereof may be of synthetic or of natural origin
- resveratrol particularly (trans)-resveratrol, of synthetic origin
- resveratrol of natural origin is used, i e , isolated from natural resveratrol sources, or as a resveratrol-containing extract from natural resveratrol sources such as grape seed extract or giant knotweed extract
- resveratrol may be used for the purposes of the invention alone, i e , as a single active component or in combination with one or more other active ingredients often used in nutritional supplemental formulations
- Such other ingredients include, but are not restricted to, mineral salts, vitamins (e g , vitamin E and C), carotenoids, such as ⁇ - carotene, lycopene, lutein or zeaxanthin, green tea catechins, such
- the gene expression profile of a mammal whose diet is supplemented with resveratrol, a derivative, metabolite or analogue thereof is closer to the profile which is found in a healthy young adult mammal than to the profile which is found in a mammal having the same chronological age and whose diet was devoid of resveratrol
- gene expression profiles in adult mammals can be changed towards conformity with expression profiles of younger adult mammals by administering to an adult mammal an effective amount of resveratrol, a derivative, metabolite or analogue thereof.
- mammals treated with resveratrol, a derivative, metabolite or analogue thereof will be in a state of wellness more similar to that of a healthy younger organism than to the average wellness state of an organism of the same age whose diet has not been supplemented with resveratrol.
- dietary resveratrol, a derivative, metabolite or analogue thereof promote the global wellness state of an organism by inducing physiological changes that will give the organism a younger phenotype.
- the promotion of wellness by dietary resveratrol in accordance with the invention improves mental fitness, enhances physical fitness, improves mobility and performance, promotes physical strength and mental strength, provides longevity and healthy aging.
- the typical result of the promotion of wellness is rejuvenation of or a rejuvenating effect on the mammal.
- the present invention is concerned with a method of promoting the wellness state of a mammal or rejuvenating a mammal, which comprises providing said mammal with an effective amount of resveratrol, a derivative, metabolite or analogue thereof.
- the provision of the active compounds of the present invention is preferably via nutraceuticals.
- the present invention is concerned with the use of resveratrol, a derivative, metabolite or analogue thereof, for the manufacture of a nutraceutical composition for promoting the wellness state of a mammal, and for changing gene expression profiles in older adult mammals towards conformity with expression profiles found in younger adult mammals which means rejuvenating said mammal.
- nutraceutical » refers to compositions for use in both the nutritional and pharmaceutical fields of application.
- a nutraceutical compositions can be a supplement to food and beverages, or a pharmaceutical formulations for enteral or parenteral application which may be solid formulations such as capsules or tablets, or liquid formulations, such as solutions or suspensions.
- the term « food » is used herein to also include animal feed.
- nutraceutical composition also comprises food and beverages containing the above-specified active ingredients as well as dosage unit compositions.
- More specific embodiments of the present invention include, but are not limited to, the use of resveratrol, a derivative, metabolite or analogue thereof, for preventing imbalances in homeostasis by improving the cellular metabolism and performance and thus improving the body performance; maintaining body mobility; improving physical and mental fitness and strength; maintaining the regenerative and repair capacity of an organism, by enhancing the ability of that organism to maintain a young state; maintaining organ function, by avoiding physiological abnormality and/ or biochemical irregularity-causing disorders; and promoting the ability of an organism to adapt to a changing environment.
- resveratrol a derivative, metabolite or analogue thereof on gene expression profiles
- effects of resveratrol, a derivative, metabolite or analogue thereof on gene expression profiles can be determined by methods known per se, e.g., as described in more detail below.
- mice Male -3603F 1 mice (6-7 weeks of age) were purchased from Harlan Sprague Dawley. Mice were housed singly and provided water ad libitum.
- Ds-cDNA was extracted with phenol-chloroform-isoamyl alcohol and precipitated with pellet paint co-precipitant (Novagen, Madison, Wl).
- Biotin-labeled RNA was synthesized in vitro using the BioArray High Yield RNA Transcript Labeling Kit (Enzo, Farmingdale, NY). The biotin-labeled antisense cRNA was then purified using the RNeasy affinity column (Qiagen) and fragmented randomly.
- the hybridization cocktail 200 ⁇ l
- 10 ⁇ g of fragmented cRNA was injected into the mouse Genome 430 2.0 DNA microarray (Affymetrix, Santa Clara, CA).
- the gene chips were washed and stained in a fluidic station (Model 800101 , Affymetrix) with a signal amplification protocol using antibody. DNA chips were scanned at a resolution of 3 ⁇ m, twice, using a Hewlett-Packard GeneArray Scanner (Model 900154, Affymetrix) and the averaged images were used for further analysis.
- a fluidic station Model 800101 , Affymetrix
- Hewlett-Packard GeneArray Scanner Model 900154, Affymetrix
- Gene expression data were obtained using the Affymetrix Mouse Genome 430 2.0 array containing 45,101 probe sets. All steps, as detailed below, were performed using the most recent version of probe set (Mouse Genome 430. 2.0 array probe set annotations available from Affymetrix at 23 August 2005). Signal intensity was determined using Affymetrix's GeneChip Operating Software version 1.3. Data analysis was performed using Genedata Expressionist ® Pro, version 2.0.
- Step 1 Data acquisition and quality control All data was imported into Genedata Expressionist ® Pro. Refiner for quality control, using Diagnose with reference module. Samples that showed a high degree of variability from other similarly treated biological replicates were removed from the data set and excluded from further analysis. Two chips (one in the YC group, one in the RES group) were eliminated due to abnormal data distribution patterns. 18 chips were further analysed using Genedata Expressionist ® Pro. Analyst.
- Step 2 Delete ambiguous probe sets
- probe sets that contain the text "_x_at” or “_s_at” do not confidently query a single gene, thus they were filtered from the data set.
- probe sets not querying well-characterized genes were eliminated from further analysis. Examples include probe sets representing cDNA sequences, expressed sequence tags (ESTs), RIKEN cDNA sequences, DNA segments or hypothetical proteins.
- genes changed with age Genes which changed with age (ageing markers) were selected by comparing YC and OC groups. To determine if there was a change in the expression of a gene with resveratrol, comparisons were made between OC and RES mice, respectively. Significantly changed genes were selected using the n-fold test, with change > 1.25-fold or consistently present in one group but absent in other groups, in combination with the two-sample test, where significance was tested at P ⁇ 0.01 (both the t-test and Welch test were used to calculate the statistical significance).
- genes which were unchanged with age were selected by comparing YC and OC groups, first filtered with a variance ⁇ 0.05, then further selected with fold of change ⁇ 1.25-fold, plus 2-group test, where significance was tested at p>0.01 (i.e. significantly unchanged between YC and OC groups).
- significantly-changed genes were determined using either fold of change (>1.25-fold) or consistently present in one group but absent in other groups. Two-tailed t-test and Welch test were both used to calculate the statistical significance, where P ⁇ 0.01 was considered as a significant change.
- Step 4 Classification using supervised learning
- Classification is a complex task which is divided into two phases, supervised learning and a test phase.
- the goal of classification is to predict an output variable (in this case, age) given an individual's input data.
- the supervised learning phase involves the application of an algorithm to training data, with the goal of learning rules by which the output variable can be predicted, while the test phase constitutes predictions being made for novel individuals, applying the rules collected in the learning phase. It is also possible to make predictions based on supplied training data.
- SVM Support Vector Machine
- Results from the resveratrol group were then analysed using the Classification function for prediction of the output variable, "Age". All 4 chips were classified as Young. A numeric value of classification output ranging from +1 to -1 was assigned to each chip, where +1 indicates a perfect match for a specific category, and -1 indicates a mismatch to the highest extent.
- Table I This table contains the numerical values of the classifier outputs from each chip; average (mean) and standard deviation are calculated for each group.
- the resveratrol group had a mean classification output of 0.34855, which is clearly much closer to the value calculated for the young group, than that of the old group.
- mice The genome-wide gene expression in heart tissue in groups of young, old and resveratrol- fed mice was monitored using the mouse Affymetrix gene array. Among the 26,000 probe sets available on the chip, 1285 genes were significantly changed between the groups of young mice and old mice (at least 1.25-fold, where p ⁇ 0.01 ). Among them, 501 genes were up- and 724 were down-regulated in the group of old mice.
- the expression of 585 genes in the resveratrol treated group were changed in the direction of the group of younger adult mice (45.5%, see table II), indicating a significant effect of resveratrol in maintaining the heart in a healthy and young state
- 342 resembled or exceeded the expression level of the young group (58.1 %); 62 genes were at a level of 80- 90% compared to the young group and 53 genes reached a level of 70- 80%. Therefore, in spite of being of the same biological age as the mice in the group of old animals, old animals fed a resveratrol-supplemented diet showed a gene profile surprisingly close to that of the young animals.
- Effect* Gene expression levels in resveratrol-fed old mice expressed as percentage of gene expression levels observed in untreated young mice.
- genes involved in protein synthesis such as eukaryotic translation initiation factors 4A1 , 2, 3, 4E, 4g1.
- genes involved in protein modification such as f-box only protein 9, homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 and ubiquitin specific protease 3 were all significantly down-regulated in the group of old animals, while these effects were reversed in the resveratrol group (see Table III)
- the present study showed that the gene expression profile of an adult mammal treated orally with resveratrol is closer to a healthy younger adult mammal than to a mammal having the same chronological age This younger gene expression profile in resveratrol treated animals promotes the state of wellness in the animalsand rejuvenates the animals
- the dosage requirements for resveratrol, a derivative, metabolite or analogue are not narrowly critical Amounts of up to about 30 mg/kg body weight per day or even higher, depending of the nature of the mammal concerned and its condition and requirements may be administered
- the dosage for a human adult (weighing about 70 kg) may be up to about 2000 mg/day
- the dosage for a human adult (weighing about 70 kg) is up to about 500 mg/day, especially up to about 500 mg/day
- the dosage is no less than 0 5 mg
- the dosage for a human adult (weighing about 70 kg) is no less than 2 mg , especially is no less than 5 mg
- the amount of resveratrol, a derivative, metabolite or analogue thereof contained therein is suitably no less than about 0 2 mg per serving In another embodiment of the invention such amount is no less than 2 mg per serving
- such amount is no less than 2 mg per serving
- serving denotes an amount of food or beverage normally ingested by a human adult with a meal at a time and may range, e.g., from about 100 g to about 500 g.
- resveratrol, a derivative, metabolite or analogue thereof may be administered as a nutritional supplement, e.g., as an additive to a multivitamin preparations comprising vitamins and minerals which are essential for the maintenance of normal metabolic function .
- Resveratrol, a derivative, metabolite or analogue thereof may be adminstered also as a pharmaceutical composition, preferably for enteral application, which may be solid or liquid galenical formulation.
- solid galenical formulations are tablets, capsules (e.g. hard or soft shell gelatin capsules), pills, sachets, powders, granules and the like which contain the active ingredient together with conventional galenical carriers. Any conventional carrier material can be utilized.
- the carrier material can be organic or inorganic inert carrier material suitable for oral administration.
- Suitable carriers include water, gelatin, gum arabic, lactose, starch, magnesium stearate, talc, vegetable oils, and the like. Additionally, additives such as flavouring agents, preservatives, stabilizers, emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding. While the individual active ingredients are suitably administered in a single composition they may also be administered in individual dosage units.
- compositions may be prepared by conventional formulation procedures
- Soft gelatin capsules are prepared by conventional procedures containing as active ingredient 30 mg of resveratrol per capsule.
- Example 2 Hard gelatin capsules are prepared by conventional procedures containing as active ingredient 20 mg of resveratrol per capsule.
- Tablets are prepared by conventional procedures containing as active ingredient 10 mg of resveratrol per tablet, and as excipients microcrystalline cellulose, silicone dioxide (SiO2), magnesium stearate, crospovidone NF (which is a disintegration agent) ad 200 mg.
- Food items may be prepared by conventional procedures containing resveratrol in an amount of 0.2 mg to 200 mg per serving. Examples of such food items are soft drinks, bread, cookies, yogurth, ice cream, and sweets.
- an orange-Lemon juice drink containing 10% juice and resveratrol is prepared from the following ingredients:
- a reconvalescent 70 year old person weighing 55 kg is administered resveratrol at a dosage regimen of 20 mg per day for a duration of 2 months.
- a person aged 55 years weighing 70 kg intending to participate in a sporting event is administered 30 mg of resveratrol per day for 3 months before said event.
- a person aged 60 years weighing 75 kg complaining of frequent episodes of tiredness and general lack of motivation is administered 50 mg of resveratrol per day for 3 months.
- .a_at protein (Protein IASPP) (PPP1 R13B-l ⁇ ke protein) (LOC243869), mRNA
- SDR family dehydrogenase/reductase
- member 5 1451519_at ring finger protein 2 1448467_a_at tangerin sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
- liver cancer 1 1436173_at deleted in liver cancer 1
- .at bicaudal D homolog 2 (Drosophila) 1423345. .at degenerative spermatocyte homolog (Drosophila) 1426403. .at ARP 1 actin-related protein 1 homolog B (yeast) 1454696. .at guanine nucleotide binding protein, beta 1 1422538 ⁇ .at exotoses (multiple)-like 2 1423041. _a_at basic leucine zipper and W2 domains 1 1448688 " .at podocalyxin-like 1448503. .at myeloid cell leukemia sequence 1 1431255. .at calreticulin 3 1418454.
- .at microfibrillar associated protein 5 1423063 " .at DNA methyltransferase 3A 1415882. .at growth hormone inducible transmembrane protein 1416320. .at SEC22 vesicle trafficking protein-like 2 (S. cerevisiae) 1450890 ⁇ .a_at abl-interactor 1 1455136. .at ATPase, Na+/K+ transporting, alpha 2 polypeptide 1418117. .at NADH dehydrogenase (ubiquinone) Fe-S protein 4 1427432 ⁇ a_at Mus musculus transcribed sequences 1424109. a_at glyoxalase 1 1425745.
- _a_at Drosophila homolog 10 (LOC229280), mRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008555674A JP2009528028A (en) | 2006-02-24 | 2007-02-14 | Use of resveratrol and its derivatives to promote health status in mammals |
US12/280,417 US20090247646A1 (en) | 2006-02-24 | 2007-02-14 | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
EP07703447A EP1986621A1 (en) | 2006-02-24 | 2007-02-14 | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06003757.9 | 2006-02-24 | ||
EP06003757A EP1825850A1 (en) | 2006-02-24 | 2006-02-24 | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
EP06009942 | 2006-05-15 | ||
EP06009942.1 | 2006-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007096078A1 true WO2007096078A1 (en) | 2007-08-30 |
Family
ID=37827426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/001256 WO2007096078A1 (en) | 2006-02-24 | 2007-02-14 | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090247646A1 (en) |
EP (1) | EP1986621A1 (en) |
JP (1) | JP2009528028A (en) |
KR (1) | KR20090003263A (en) |
WO (1) | WO2007096078A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009056212A1 (en) * | 2007-10-29 | 2009-05-07 | Dsm Ip Assets B.V. | Compositions containing resveratrol and pectin |
JP2010024208A (en) * | 2008-07-23 | 2010-02-04 | Shiseido Co Ltd | Ucp2 expression promotor |
WO2012061907A2 (en) | 2010-11-10 | 2012-05-18 | Katholieke Universiteit Leuven | Osteoclast activity |
JP2015091246A (en) * | 2008-07-18 | 2015-05-14 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Method for enhancing quality of life of senior animal |
US9782375B2 (en) * | 2015-10-28 | 2017-10-10 | Shil Kothari | Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma |
US9844526B2 (en) * | 2015-10-28 | 2017-12-19 | Gateway Health Alliances, Inc. | Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma |
US11241396B2 (en) * | 2015-10-28 | 2022-02-08 | Gateway Health Alliances, Inc. | Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008088123A (en) * | 2006-10-03 | 2008-04-17 | Oriza Yuka Kk | Skin-beautifying composition |
JP5948871B2 (en) * | 2011-12-28 | 2016-07-06 | 株式会社東洋新薬 | Polyphenol-containing composition |
CN116593717B (en) * | 2023-07-18 | 2023-09-26 | 首都医科大学附属北京口腔医院 | Application of synaptic fusion protein 8 in detection of mitochondrial injury |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082203A1 (en) * | 2001-10-30 | 2003-05-01 | Farley Michael D. | Immune functions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2790645B1 (en) * | 1999-03-12 | 2001-06-08 | Arkopharma Laboratoires | FOOD SUPPLEMENT AND COSMETIC TREATMENT METHOD BASED ON GRAPE EXTRACT RICH IN POLYPHENOLS |
JP2001069948A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Food for prevention of senescence |
JP2001072582A (en) * | 1999-09-07 | 2001-03-21 | Sunstar Inc | Functional oral composition |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
WO2004105517A1 (en) * | 2003-05-27 | 2004-12-09 | Dsm Ip Assets B.V. | Novel nutraceutical compositions and use thereof |
JP4963670B2 (en) * | 2004-04-07 | 2012-06-27 | レスベラトロル パートナーズ, エルエルシー | Nutritional supplements and methods for processing them |
-
2007
- 2007-02-14 KR KR1020087023359A patent/KR20090003263A/en not_active Application Discontinuation
- 2007-02-14 EP EP07703447A patent/EP1986621A1/en not_active Withdrawn
- 2007-02-14 WO PCT/EP2007/001256 patent/WO2007096078A1/en active Application Filing
- 2007-02-14 JP JP2008555674A patent/JP2009528028A/en active Pending
- 2007-02-14 US US12/280,417 patent/US20090247646A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082203A1 (en) * | 2001-10-30 | 2003-05-01 | Farley Michael D. | Immune functions |
Non-Patent Citations (7)
Title |
---|
BAGCHI D ET AL: "PHYTOESTROGEN, RESVERATROL AND WOMEN'S HEALTH", RESEARCH COMMUNICATIONS IN PHARMACOLOGY AND TOXICOLOGY, PJD PUBLICATIONS, WESTBURY, NY, US, vol. 5, no. 1/2, 2000, pages 107 - 121, XP001018765, ISSN: 1087-1101 * |
CHRISTENSEN H ET AL: "Age differences in depression and anxiety symptoms: a structural equation modelling analysis of data from a general population sample.", PSYCHOLOGICAL MEDICINE MAR 1999, vol. 29, no. 2, March 1999 (1999-03-01), pages 325 - 339, XP009080777, ISSN: 0033-2917 * |
DELMAS DOMINIQUE ET AL: "Resveratrol: Preventing properties against vascular alterations and ageing", MOLECULAR NUTRITION & FOOD RESEARCH, vol. 49, no. 5, May 2005 (2005-05-01), pages 377 - 395, XP002378878, ISSN: 1613-4125 * |
DORE SYLVAIN: "Unique properties of polyphenol stilbenes in the brain: More than direct antioxidant actions; Gene/protein regulatory activity", NEUROSIGNALS, vol. 14, no. 1-2, 2005, pages 61 - 70, XP009065799, ISSN: 1424-862X * |
FENG YONG-HONG ET AL: "Low dose of resveratrol enhanced immune response of mice", ACTA PHARMACOLOGICA SINICA, vol. 23, no. 10, October 2002 (2002-10-01), pages 893 - 897, XP002378877, ISSN: 1671-4083 * |
SOLEAS G J ET AL: "RESVERATROL: A MOLECULE WHOSE TIME HAS COME? AND GONE?", CLINICAL BIOCHEMISTRY, PERGAMON PRESS, vol. 30, no. 2, March 1997 (1997-03-01), pages 91 - 113, XP000856542, ISSN: 0009-9120 * |
VALENZANO DARIO R ET AL: "Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate.", CURRENT BIOLOGY : CB. 7 FEB 2006, vol. 16, no. 3, 7 February 2006 (2006-02-07), pages 296 - 300, XP005276165, ISSN: 0960-9822 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009056212A1 (en) * | 2007-10-29 | 2009-05-07 | Dsm Ip Assets B.V. | Compositions containing resveratrol and pectin |
JP2011500737A (en) * | 2007-10-29 | 2011-01-06 | ディーエスエム アイピー アセッツ ビー.ブイ. | Composition containing resveratrol and pectin |
US8535724B2 (en) | 2007-10-29 | 2013-09-17 | Dsm Ip Assets B.V. | Compositions containing resveratrol and pectin |
JP2015091246A (en) * | 2008-07-18 | 2015-05-14 | ヒルズ・ペット・ニュートリシャン・インコーポレーテッド | Method for enhancing quality of life of senior animal |
JP2010024208A (en) * | 2008-07-23 | 2010-02-04 | Shiseido Co Ltd | Ucp2 expression promotor |
WO2012061907A2 (en) | 2010-11-10 | 2012-05-18 | Katholieke Universiteit Leuven | Osteoclast activity |
US9782375B2 (en) * | 2015-10-28 | 2017-10-10 | Shil Kothari | Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma |
US9844526B2 (en) * | 2015-10-28 | 2017-12-19 | Gateway Health Alliances, Inc. | Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma |
US11241396B2 (en) * | 2015-10-28 | 2022-02-08 | Gateway Health Alliances, Inc. | Methods and compositions for improving microvascular function, suppressing cyclooxygenase activity, reducing platelet aggregation and increasing levels of resveratrol in plasma |
Also Published As
Publication number | Publication date |
---|---|
JP2009528028A (en) | 2009-08-06 |
US20090247646A1 (en) | 2009-10-01 |
EP1986621A1 (en) | 2008-11-05 |
KR20090003263A (en) | 2009-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1986621A1 (en) | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals | |
Fuertig et al. | Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: Both effects are reversed by inhibition of indoleamine 2, 3-dioxygenase | |
Hu et al. | Quercetin regulates organic ion transporter and uromodulin expression and improves renal function in hyperuricemic mice | |
JP2017214413A (en) | Methods for treating metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers | |
Gardner et al. | Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders | |
US20080300198A1 (en) | Olive Compositions and Methods for Treating Inflammatory Conditions | |
AU2014228785B2 (en) | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction | |
Al Za’abi et al. | Development of a new model for the induction of chronic kidney disease via intraperitoneal adenine administration, and the effect of treatment with gum acacia thereon | |
US20070213282A1 (en) | Peroxisome proliferator-activated receptor (PPAR) activator, and drugs, supplements, functional foods and food additives using the same | |
US20110257256A1 (en) | Cannabinoids for use in treating or preventing cognitive impairment and dementia | |
JP2005506996A (en) | Curcuminoid composition exhibiting synergistic inhibition of cyclooxygenase-2 expression and / or activity | |
JP2009203244A (en) | Complicated mixture exhibiting selective inhibition of cyclooxygenase 2 | |
KR20070024500A (en) | Synergistic anti-inflammatory pharmaceutical compositions and methods of use | |
US20100234402A1 (en) | Methods and compositions for treating spinal muscular atrophy | |
WO2018118197A1 (en) | Healthier aging in domesticated animals | |
Gharaei et al. | Randomized controlled trial of astaxanthin impacts on antioxidant status and assisted reproductive technology outcomes in women with polycystic ovarian syndrome | |
Kandeil et al. | Wheat germ and vitamin E decrease BAX/BCL-2 ratio in rat kidney treated with gentamicin | |
EP1825850A1 (en) | Use of resveratrol and derivatives thereof for promoting the wellness state in mammals | |
Kim et al. | Anti-hyperglycemic potential of alginate oligosaccharide in a high glucose-induced zebrafish model | |
DeLisi et al. | Phenylethylamine excretion in depression | |
CA2832059C (en) | Inflammation and immunity treatments | |
EP4161550A1 (en) | Shan-zha for the treatment of depression and anxiety disorders | |
EP4117455A2 (en) | Novel nutrients to enhance load-induced muscle hypertrophy | |
US20200319198A1 (en) | Olive compositions and methods for treating inflammatory conditions | |
Manzardo | Thiamine deficiency and alcoholism psychopathology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007703447 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008555674 Country of ref document: JP Ref document number: 200780006623.8 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8009/DELNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087023359 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12280417 Country of ref document: US |